Search dm+d | Analyse prescribing for this drug | See prices paid for this drug and its variants
Name | Reboxetine 4mg tablets |
BNF code | 0403040U0AAAAAA |
Virtual Therapeutic Moiety | Reboxetine |
Date identifier became valid | 26 May 2021 |
Previous product identifier | 321996003 |
Basis of preferred name | rINN - Recommended International Non-proprietary |
Prescribing status | Valid as a prescribable product |
Sugar free | ✗ |
Gluten free | ✗ |
Preservative free | ✗ |
CFC free | ✗ |
Dose form | Discrete |
Unit dose form size | 1.000 |
Unit dose form units | tablet |
Unit dose unit of measure | tablet |
Virtual Product Ingredient | |
---|---|
Ingredient | Reboxetine mesilate |
Basis of pharmaceutical strength | Based on Base Substance |
Basis of strength substance identifier | 395859006 |
Strength value numerator | 4.000 |
Strength value numerator unit | mg |
Ontology Drug Form & Route | |
Form & Route | tablet.oral |
Dose Form | |
Formulation | Oral tablet |
Drug Route | |
Route | Oral |
Controlled Drug Prescribing Information | |
Controlled Drug category | No Controlled Drug Status |
Actual Medicinal Products | |
Edronax 4mg tablets (CST Pharma Ltd) | |
Edronax 4mg tablets (Lexon (UK) Ltd) | |
Edronax 4mg tablets (Pfizer Ltd) | |
Edronax 4mg tablets (Sigma Pharmaceuticals Plc) | |
Virtual Medicinal Product Packs | |
Reboxetine 4mg tablets 20 tablet | |
Reboxetine 4mg tablets 60 tablet |
dm+d data retrieved from TRUD: release NHSBSA_12.3.0_20241223000001, imported on 24th December 2024 at 03:51:32.